Portfolio
0
in our dataset
Rounds participated
0
Rounds led
0
Disclosed deployed
—
across known amounts
Stages
—
About
The Office of the Chief Scientist is a unit responsible for leading the State of Israel to the forefront of science and future technologies and maintaining its leading position. This is by identifying areas of national priority and identifying future trends in the fields of science and technology and promoting them actively and horizontally, conducting ongoing monitoring of developments in science and technology in Israel and around the world. In 2016, the Office of the Chief Scientist was replaced by the Innovation Authority.
Portfolio
No portfolio companies in this dataset yet.
Investor Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is the primary operational focus of the Office of the Chief Scientist?
- The Office of the Chief Scientist is responsible for leading Israel in science and future technologies by identifying national priority areas, monitoring global developments, and actively promoting these fields. In 2016, it was replaced by the Innovation Authority.
- When was the Office of the Chief Scientist founded and where is it headquartered?
- The Office of the Chief Scientist was founded in 1965 and is headquartered in Jerusalem, Israel.
- What is the investment range for the Office of the Chief Scientist?
- The Office of the Chief Scientist's investment range is between $160K and $8M per investment.
- Which sector has received the most investments from the Office of the Chief Scientist?
- Health Tech & Life Sciences is the most invested sector, with 28 rounds of funding from the Office of the Chief Scientist.
- Can you name some notable portfolio companies of the Office of the Chief Scientist?
- Notable portfolio companies include TytoCare, which has raised $203.6M, and Velox, which has raised $109.5M. For a full list, refer to startupim data.
- Has the Office of the Chief Scientist had any exits, and if so, which companies?
- Yes, the Office of the Chief Scientist has had several exits. BELKIN Vision was acquired by Alcon Pharmaceuticals in July 2024 for $81M, and Fieldbit was acquired by Help Lightning in November 2021.
- What was the most recent investment made by the Office of the Chief Scientist?
- The most recent investment by the Office of the Chief Scientist was in ZevaLed in April 2018, with an amount of $2,500,000.
- What is the Office of the Chief Scientist's activity regarding lead investments?
- According to startupim data, the Office of the Chief Scientist has a lead investor share of 0%, indicating it does not typically act as a lead investor in its funding rounds.